【摘要】 目的:临床验证双歧杆菌、肠球菌、乳杆菌和芽孢杆菌四联活菌肠溶胶囊治疗慢性腹泻的疗效及安全性。方法:采用多中心、随机、盲法平行对照研究方法。试验组124例给予双歧杆菌、肠球菌、乳杆菌和芽孢杆菌四联活菌肠溶胶囊治疗,对照组80例给予双歧三联活菌胶囊(含长型双歧杆菌、嗜酸乳杆菌和粪肠球菌)治疗,疗程14d,观察腹泻缓解时间及腹泻伴随症状(腹痛、腹胀、里急后重等)变化。结果:试验组3d时腹泻缓解率为41.13%,优于对照组的11.25%(P<0.05);疗程结束时试验组腹泻缓解率为90.32%,大便成形率为75.81%,腹泻伴随症状明显下降,与对照组比较有显著性差异(P<0.05)。结论:双歧杆菌、肠球菌、乳杆菌和芽孢杆菌四联活菌肠溶胶囊治疗慢性腹泻安全、有效。更多还原

【Abstract】 OBJECTIVE: To validate the efficacy and safety of the enteric-coated capsule of Four Viable Organisms(bafidobacterium,lactobacillus,enterococcus and bacilluscereus) in the treatment of chronic diarrhea.METHODS: In this multi-center,randomized,blind control study,124 patients(trial group) with chronic diarrhea were randomly assigned to receive the enteric-coated capsule containing bacillus bifidus,lactobacillus,enterococcus and bacilluscereus,while the control group(n=80) to receive the capsule of bacillus bifidus,bacillus acidophilus and enterococcus faecalis for 14 days.The days spent for the relief of diarrhea relief and the concomitant symptoms of diarrhea such as pain,bloating,and tenesmus were observed.RESULTS: At 3 days,the remission rate in trial group(41.13%) was higher than in control group(11.25%)(P< 0.05).In the trial group after the completion of 14-day treatment,the remission rate reached 90.32%,75.81% of the stool was in normal shape,the concomitant symptoms of diarrhea improved significantly,all showing significant differences as compared with control group(P<0.05).CONCLUSION: The capsule containing bafidobacterium,lactobacillus,enterococcus and bacilluscereus is an effective and safe agent for chronic diarrhea.更多还原